Moderna’s AI-Built Cancer Vaccine Clears Phase 3 With Merck
Moderna built an artificial intelligence that reads a patient’s tumor and decides what that patient’s medicine should be. That approach just cleared its biggest test. Moderna and Merck announced Aug. 19 that their Phase 3 trial of intismeran autogene, a cancer therapy built individually for each patient, met its primary endpoint in melanoma patients whose […] The post Moderna’s AI-Built Cancer…
Moderna's AI-driven cancer vaccine, developed in collaboration with Merck, has successfully completed its Phase 3 trial in melanoma patients. The innovative treatment, known as intismeran autogene, is personalized for each patient, constructed by sequencing their tumor and identifying targeted mutations. This groundbreaking approach has been hailed as a "pivotal moment" for cancer research, according to Moderna CEO Stéphane Bancel.
The AI system not only accelerates research but also directly influences the individualized product. However, the manufacturing process poses challenges, as each dose is unique, leading to a turnaround time of four to eight weeks from biopsy to dose. While the scientific aspect is proving successful, the economic viability of scaling this personalized medicine remains uncertain.
Modana plans to apply the same AI-driven strategy to other cancers, such as lung, kidney, and bladder cancer, in upcoming trials. The success of this approach will determine whether individualized cancer therapy will become a mainstream treatment or remain a costly niche option.
Written by urgent.news from PYMNTS's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
